SOST and Marchiafava-Bignami disease: Serum sclerostin has been predicted as a potential sensitive indicator of the occurrence of CKD-MBD, and due to its close relationship to the prognosis of CKD, there has been a proposed association of sclerostin’s involvement in CKD pathogenesis [205].